Pacira BioSciences (PCRX) to Release Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) will likely be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Pacira BioSciences to post earnings of $0.78 per share and revenue of $185.38 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $25.10 on Wednesday. The firm has a fifty day moving average of $22.71 and a two-hundred day moving average of $18.31. The firm has a market cap of $1.16 billion, a P/E ratio of -12.36 and a beta of 0.80. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Analyst Ratings Changes

A number of equities analysts recently commented on PCRX shares. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC lifted their target price on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays decreased their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $22.78.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.